Horst Irlbacher

USPTO Granted Patents = 7 (Patent Applications = 8)

CIPO Patents = 1 (Patent Applications = 10)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 8.7

ph-index = 1

Forward Citations = 20(Granted Patents)

Company Filing History:

7 out of 378

Bayer Pharma Aktiengesellschaft

patents

2 out of 155

Deutsches Krebsforschungszentrum

patents

1 out of 12,160

Bayer Aktiengesellschaft

patents

where one patent can have more than one assignee

Years Active: 2018-2023

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11795164 - 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer (2023-10-24),

2. 11040035 - 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides (2021-06-22),

3. 10894805 - Prodrugs of the selective progesterone receptor modulator (SPRM) (11.beta.,17.beta.)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl] -17-(pentafluoroethyl)estra-4,9-dien-3-one (2021-01-19),

4. 10894784 - Heteroarylbenzimidazole compounds (2021-01-19),

5. 10172814 - Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof (2019-01-08),

6. 10167293 - [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones (2019-01-01),

7. 9951086 - Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments (2018-04-24),

Title: Horst Irlbacher - Pioneering Cancer Treatment Innovations

Introduction:

Horst Irlbacher is a distinguished inventor based in Berlin, Germany, with a strong passion for revolutionizing the field of pharmaceuticals. With an impressive portfolio of 7 patents, he has made significant contributions to the development of novel compounds for cancer treatment.

Latest Patents:

1. 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides: Horst Irlbacher's latest patent encompasses compounds designed for the treatment of cancer and other related conditions with dysregulated immune responses. These compounds hold promise for manufacturing pharmaceutical compositions aimed at combatting these challenging diseases.

2. 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides: Another groundbreaking invention by Horst Irlbacher, focusing on compounds that show potential in treating cancer and conditions associated with aberrant AHR signaling. These compounds may be utilized as standalone treatments or in combination with other active ingredients for enhanced efficacy.

Career Highlights:

Horst Irlbacher has garnered extensive experience and expertise during his tenure at prestigious companies such as Bayer Pharma Aktiengesellschaft and the Deutsches Krebsforschungszentrum. His innovative spirit and commitment to advancing cancer therapeutics have set him apart as a key figure in the pharmaceutical industry.

Collaborations:

Throughout his career, Horst Irlbacher has collaborated closely with notable colleagues, including Benjamin Bader and Detlef Stöckigt. These collaborations have resulted in fruitful exchanges of ideas and insights, contributing to the successful development of groundbreaking pharmaceutical compounds.

Conclusion:

In conclusion, Horst Irlbacher's relentless pursuit of innovation in cancer treatment has led to the creation of novel compounds with the potential to transform the pharmaceutical landscape. His dedication to advancing medical science underscores his invaluable contributions to the fight against cancer and other challenging diseases.

This text is generated by artificial intelligence and may not be accurate.